Longitudinal antibody titer, avidity, and neutralizing responses after SARS-CoV-2 infection

Longitudinal antibody titer, avidity, and neutralizing responses after SARS-CoV-2 infection

While waning immunity and SARS-CoV-2 variant immune escape continue to result in high infection rates worldwide, associations between longitudinal quantitative, qualitative, and functional humoral immune responses after SARS-CoV-2 infection remain unclear. In this study, we found significant waning...

Full description

Bibliographic Details
Main Authors:	Jonathon M. Monroe, Iana H. Haralambieva, Nathaniel D. Warner, Diane E. Grill, Huy Quang Quach, Richard B. Kennedy
Format:	Article
Language:	English
Published:	Elsevier 2022-11-01
Series:	Heliyon
Subjects:	SARS-CoV-2 COVID-19 Antibody avidity Neutralization Humoral immunity Longitudinal immunity
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405844022029644

Similar Items

Retained avidity despite reduced cross-binding and cross-neutralizing antibody levels to Omicron after SARS-COV-2 wild-type infection or mRNA double vaccination
by: Teresa Harthaller, et al.
Published: (2023-07-01)

High avidity of vaccine-induced immunoglobulin G against SARS-CoV-2: potential relevance for protective humoral immunity
by: Georg Bauer
Published: (2022-03-01)

BNT162b2 mRNA SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers
by: Federico Pratesi, et al.
Published: (2021-06-01)

Leptospirosis severity may be associated with the intensity of humoral immune response
by: Regina C.R.M. ABDULKADER, et al.
Published: (2002-04-01)

Clinical Utility of SARS-CoV-2 Antibody Titer Multiplied by Binding Avidity of Receptor-Binding Domain (RBD) in Monitoring Protective Immunity and Clinical Severity
by: Etsuhisa Takahashi, et al.
Published: (2023-07-01)

T Cell Transcriptional Signatures of Influenza A/H3N2 Antibody Response to High Dose Influenza and Adjuvanted Influenza Vaccine in Older Adults
by: Iana H. Haralambieva, et al.
Published: (2022-12-01)

Profiling of Measles-Specific Humoral Immunity in Individuals Following Two Doses of MMR Vaccine Using Proteome Microarrays
by: Iana H. Haralambieva, et al.
Published: (2015-03-01)

Analyzing features of measles immune response in adult patients
by: Anna P. Toptygina, et al.
Published: (2023-10-01)

Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants
by: Wenjuan Du, et al.
Published: (2023-02-01)

Salivary anti-PGL IgM and IgA titers and serum antibody IgG titers and avidities in leprosy patients and their correlation with time of infection and antigen exposure
by: Aparecida T. Nagao-Dias, et al.

Early B cell transcriptomic markers of measles-specific humoral immunity following a 3rd dose of MMR vaccine
by: Iana H. Haralambieva, et al.
Published: (2024-04-01)

Longitudinal Assessment of BNT162b2- and mRNA-1273-Induced Anti-SARS-CoV-2 Spike IgG Levels and Avidity Following Three Doses of Vaccination
by: Jimmie L. Bullock, et al.
Published: (2024-05-01)

EPSTEIN-BARR VIRUS INFECTIONS – AVIDITY TEST FOR IgG ANTIBODIES
by: Katja Strašek, et al.
Published: (2001-06-01)

Avid made easy : video editing with Avid Free DV and the Avid Xpress family /
by: 320615 Fowler, Jaime
Published: (2005)

RBD and Spike DNA-Based Immunization in Rabbits Elicited IgG Avidity Maturation and High Neutralizing Antibody Responses against SARS-CoV-2
by: Hernan H. M. da Costa, et al.
Published: (2023-02-01)

Avid made easy [compact disc] : video editing with Avid Free DV and the Avid Xpress family /
by: 320615 Fowler, Jaime
Published: (2005)

Kinetics of foot-and-mouth disease vaccine-induced antibody responses in buffaloes (Bubalus bubalis): avidity ELISA as an alternative to the virus neutralization test
by: Juan Manuel Sala, et al.
Published: (2023-11-01)

Modified ELISA for antibody avidity evaluation: The need for standardization
by: Victor Araujo Correa, et al.
Published: (2021-08-01)

Evaluation of Monkeypox- and Vaccinia virus-neutralizing antibodies in human serum samples after vaccination and natural infection
by: Alessandro Manenti, et al.
Published: (2023-06-01)

Asymmetric ventriculomegaly, interhemispheric cyst, and dysgenesis of corpus callosum (AVID) - case report
by: Prakash Dhakal, MD, et al.
Published: (2023-11-01)

AVIDITY EVALUATION OF LOCAL IgA ANTIBODIES IN PERSONS IMMUNIZED WITH LIVE INFLUENZA VACCINE
by: S. A. Donina, et al.
Published: (2014-07-01)

Antibody avidity to pertussis toxin after acellular pertussis vaccination and infection
by: Aapo Knuutila, et al.
Published: (2023-12-01)

Diagnosis of Acute Toxoplasmosis in the First Trimester of Pregnancy by IgG Avidity
by: Afshin Azimi, et al.
Published: (2022-06-01)

Finally neutralizing the threat? A novel SARS-CoV-2 vaccine platform that elicits enhanced neutralizing antibody responses
by: Daniel J. Salamango
Published: (2024-04-01)

Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults
by: Karina Takesaki Miyaji, et al.

Areas of Uncertainty in SARS-CoV-2 Vaccination for Cancer Patients
by: Anastasios Dimou
Published: (2022-12-01)

Dot-enzyme-linked immunosorbent assay (dot-ELISA) for evaluating IgG antibody avidity in toxoplasmosis
by: Fabio G. Melo, et al.
Published: (1997-07-01)

Humoral Immunity of Unvaccinated COVID-19 Recovered vs. Naïve BNT162b2 Vaccinated Individuals: A Prospective Longitudinal Study
by: Gili Joseph, et al.
Published: (2023-06-01)

Diagnosis of Toxoplasmosis in Pregnant Women by IgG Avidity Assay
by: M. Roozbehani, et al.
Published: (2015-02-01)

Determination the Time of Toxoplasmosis among Pregnant Women by using IgG Avidity to Various Toxoplasma Gondii Antigens
by: Sanarya Tawfiq, et al.
Published: (2019-03-01)

High-Avidity Anti-Filovirus IgG Elicited Using Protein Subunit Vaccines Does Not Correlate with Protection
by: Caitlin A. Williams, et al.
Published: (2023-10-01)

Sclerosing hemangioma of the lung showing strong FDG avidity on PET scan: Case report and review of the current literature
by: Davide Patrini, et al.
Published: (2016-01-01)

Evaluation of an in-house specific immunoglobulin G (IgG) avidity ELISA for distinguishing recent primary from long-term human cytomegalovirus (HCMV) infection
by: Silmara de Souza, et al.
Published: (2003-12-01)

Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity
by: Allison M. Brady, et al.
Published: (2020-08-01)

Seropositivity of Cytomegalovirus, Rubella and Toxoplasma Gondii in Pregnant Women and IgG Avidity Tests
by: Cemal ÇİÇEK, et al.
Published: (2023-04-01)

Continuous HIV-1 Escape from Autologous Neutralization and Development of Cross-Reactive Antibody Responses Characterizes Slow Disease Progression of Children
by: Stefania Dispinseri, et al.
Published: (2021-03-01)

Relationship of IgG Avidity Index and IgM Levels for the Differential Diagnosis of Primary from Recurrent Cytomegalovirus Infections
by: Anita Chakravarti, et al.
Published: (2007-12-01)

Previous exposure to Spike-providing parental strains confers neutralizing immunity to XBB lineage and other SARS-CoV-2 recombinants in the context of vaccination
by: Rahul K. Suryawanshi, et al.
Published: (2023-12-01)

Strength and Numbers: The Role of Affinity and Avidity in the ‘Quality’ of T Cell Tolerance
by: Sébastien This, et al.
Published: (2021-06-01)

IgG Avidity Test in Congenital Toxoplasmosis Diagnoses in Newborns
by: Zulmirene Cardoso Fonseca, et al.
Published: (2017-06-01)